0001315863-18-000867.txt : 20181114 0001315863-18-000867.hdr.sgml : 20181114 20181114101747 ACCESSION NUMBER: 0001315863-18-000867 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(7) FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 EFFECTIVENESS DATE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Drug Royalty IV, L.P. CENTRAL INDEX KEY: 0001756700 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-325733 FILM NUMBER: 181181090 BUSINESS ADDRESS: STREET 1: 100 KING STREET WEST STREET 2: SUITE 7250 CITY: TORONTO STATE: A6 ZIP: M5X 1B1 BUSINESS PHONE: 416.324.5714 MAIL ADDRESS: STREET 1: 100 KING STREET WEST STREET 2: SUITE 7250 CITY: TORONTO STATE: A6 ZIP: M5X 1B1 D 1 primary_doc.xml X0708 D LIVE 0001756700 Drug Royalty IV, L.P. 100 KING STREET WEST SUITE 7250 TORONTO A6 ONTARIO, CANADA M5X 1B1 416.324.5714 DELAWARE None None Limited Partnership true 2018 N/A Drug Royalty IV GP, LLC 100 King Street West Suite 7250 Toronto A6 ONTARIO, CANADA M5X 1B1 Executive Officer Promoter Drug Royalty IV GP, LLC is the general partner of the Issuer. N/A DRI Capital, Inc. 100 King Street West Suite 7250 Toronto A6 ONTARIO, CANADA M5X 1B1 Promoter DRI Capital, Inc. is the investment manager of the Issuer. Behzad Khosrowshahi 100 King Street West Suite 7250 Toronto A6 ONTARIO, CANADA M5X 1B1 Executive Officer Mr. Khosrowshahi is the CEO of DRI Capital, Inc., the investment manager of the Issuer. Andrea Sotak 100 King Street West Suite 7250 Toronto A6 ONTARIO, CANADA M5X 1B1 Executive Officer Ms. Sotak is the President and CIO of DRI Capital, Inc. the investment manager of the Issuer. Pooled Investment Fund Private Equity Fund false Decline to Disclose 06b 3C 3C.7 false true true true true false 0 Indefinite 0 Indefinite false 0 0 0 0 The investment manager is entitled to a management fee. The general partner is entitled to a performance allocation. The terms of the management fee and performance allocation are fully discussed in the Issuer's confidential offering materials. false Drug Royalty IV, L.P. /s/ Behzad Khosrowshahi Behzad Khosrowshahi CEO of the Issuer's Investment Manager 2018-11-14